Cargando…
Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs and speed up the development process of anti-cancer drug designs has become a challenging and urgent question for the pharmaceutical industry. Computer-ai...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963982/ https://www.ncbi.nlm.nih.gov/pubmed/37259400 http://dx.doi.org/10.3390/ph16020253 |
_version_ | 1784896389970395136 |
---|---|
author | Wang, Liuying Song, Yongzhen Wang, Hesong Zhang, Xuan Wang, Meng He, Jia Li, Shuang Zhang, Liuchao Li, Kang Cao, Lei |
author_facet | Wang, Liuying Song, Yongzhen Wang, Hesong Zhang, Xuan Wang, Meng He, Jia Li, Shuang Zhang, Liuchao Li, Kang Cao, Lei |
author_sort | Wang, Liuying |
collection | PubMed |
description | Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs and speed up the development process of anti-cancer drug designs has become a challenging and urgent question for the pharmaceutical industry. Computer-aided drug design methods have played a major role in the development of cancer treatments for over three decades. Recently, artificial intelligence has emerged as a powerful and promising technology for faster, cheaper, and more effective anti-cancer drug designs. This study is a narrative review that reviews a wide range of applications of artificial intelligence-based methods in anti-cancer drug design. We further clarify the fundamental principles of these methods, along with their advantages and disadvantages. Furthermore, we collate a large number of databases, including the omics database, the epigenomics database, the chemical compound database, and drug databases. Other researchers can consider them and adapt them to their own requirements. |
format | Online Article Text |
id | pubmed-9963982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99639822023-02-26 Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade Wang, Liuying Song, Yongzhen Wang, Hesong Zhang, Xuan Wang, Meng He, Jia Li, Shuang Zhang, Liuchao Li, Kang Cao, Lei Pharmaceuticals (Basel) Review Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs and speed up the development process of anti-cancer drug designs has become a challenging and urgent question for the pharmaceutical industry. Computer-aided drug design methods have played a major role in the development of cancer treatments for over three decades. Recently, artificial intelligence has emerged as a powerful and promising technology for faster, cheaper, and more effective anti-cancer drug designs. This study is a narrative review that reviews a wide range of applications of artificial intelligence-based methods in anti-cancer drug design. We further clarify the fundamental principles of these methods, along with their advantages and disadvantages. Furthermore, we collate a large number of databases, including the omics database, the epigenomics database, the chemical compound database, and drug databases. Other researchers can consider them and adapt them to their own requirements. MDPI 2023-02-07 /pmc/articles/PMC9963982/ /pubmed/37259400 http://dx.doi.org/10.3390/ph16020253 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wang, Liuying Song, Yongzhen Wang, Hesong Zhang, Xuan Wang, Meng He, Jia Li, Shuang Zhang, Liuchao Li, Kang Cao, Lei Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade |
title | Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade |
title_full | Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade |
title_fullStr | Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade |
title_full_unstemmed | Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade |
title_short | Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade |
title_sort | advances of artificial intelligence in anti-cancer drug design: a review of the past decade |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963982/ https://www.ncbi.nlm.nih.gov/pubmed/37259400 http://dx.doi.org/10.3390/ph16020253 |
work_keys_str_mv | AT wangliuying advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT songyongzhen advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT wanghesong advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT zhangxuan advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT wangmeng advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT hejia advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT lishuang advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT zhangliuchao advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT likang advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade AT caolei advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade |